O	0	1	A
O	2	12	randomized
O	12	13	,
O	14	24	controlled
O	24	25	,
O	26	32	double
O	32	33	-
O	33	38	blind
O	39	44	study
O	45	47	of
B-intervention	48	53	light
I-intervention	54	62	emitting
I-intervention	63	68	diode
I-intervention	69	84	photomodulation
O	85	88	for
O	89	92	the
O	93	103	prevention
O	104	106	of
B-condition	107	116	radiation
I-condition	117	127	dermatitis
O	128	130	in
O	131	139	patients
O	140	144	with
O	145	151	breast
O	152	158	cancer
O	158	159	.

O	160	169	Radiation
O	170	180	dermatitis
O	181	187	occurs
O	188	190	in
O	191	192	a
O	193	201	majority
O	202	204	of
O	205	213	patients
O	214	218	with
O	219	225	breast
O	226	232	cancer
O	233	236	who
O	237	244	receive
O	245	254	radiation
O	255	262	therapy
O	263	264	(
O	264	266	RT
O	266	267	)
O	267	268	,
O	269	275	causes
O	276	287	significant
O	288	292	pain
O	292	293	,
O	294	297	and
O	298	301	may
O	302	313	necessitate
O	314	323	treatment
O	324	329	delay
O	329	330	.

O	331	336	Light
O	337	345	emitting
O	346	351	diode
O	352	353	(
O	353	356	LED
O	356	357	)
O	358	373	photomodulation
O	374	377	has
O	378	382	been
O	383	391	reported
O	392	394	to
O	395	403	minimize
O	404	413	radiation
O	414	424	dermatitis
O	424	425	.

O	426	430	This
O	431	436	study
O	437	443	sought
O	444	446	to
O	447	454	further
O	455	463	evaluate
O	464	467	the
O	468	476	efficacy
O	477	479	of
O	480	483	LED
O	484	499	photomodulation
O	500	502	in
O	503	512	lessening
O	513	522	radiation
O	523	533	dermatitis
O	533	534	.

O	535	540	After
O	541	548	surgery
O	548	549	,
O	550	558	patients
O	559	563	with
O	564	570	breast
O	571	577	cancer
O	578	586	received
O	587	590	LED
O	591	606	photomodulation
O	607	609	or
B-control	610	614	sham
I-control	615	625	treatments
O	626	628	in
O	629	640	conjunction
O	641	645	with
O	646	651	three
O	651	652	-
O	652	663	dimensional
O	664	673	conformal
O	674	676	RT
O	676	677	.

O	678	687	Reactions
O	688	692	were
O	693	702	evaluated
O	703	708	using
O	709	721	standardized
O	722	733	photographs
O	734	740	graded
O	741	750	according
O	751	753	to
O	754	762	National
O	763	769	Cancer
O	770	779	Institute
O	780	788	criteria
O	788	789	.

O	790	792	In
O	793	796	the
O	797	800	LED
O	801	810	treatment
O	811	816	group
O	817	818	(
O	818	819	n
O	819	820	=
B-total-participants	820	822	18
O	822	823	)
O	823	824	,
B-iv-bin-abs	825	827	no
O	828	836	patients
O	837	840	had
B-outcome	841	846	grade
I-outcome	847	848	0
I-outcome	849	858	reactions
O	858	859	,
B-iv-bin-abs	860	863	six
O	864	865	(
B-iv-bin-percent	865	867	33
I-iv-bin-percent	867	868	.
I-iv-bin-percent	868	869	3
I-iv-bin-percent	869	870	%
O	870	871	)
O	872	875	had
B-outcome	876	881	grade
I-outcome	882	883	1
I-outcome	884	893	reactions
O	893	894	,
B-iv-bin-abs	895	897	12
O	898	899	(
B-iv-bin-percent	899	901	66
I-iv-bin-percent	901	902	.
I-iv-bin-percent	902	903	7
I-iv-bin-percent	903	904	%
O	904	905	)
O	906	909	had
B-outcome	910	915	grade
I-outcome	916	917	2
I-outcome	918	927	reactions
O	927	928	,
O	929	932	and
B-iv-bin-abs	933	937	none
O	938	941	had
O	942	943	a
B-outcome	944	949	grade
I-outcome	950	951	3
I-outcome	952	960	reaction
O	960	961	.

O	962	964	In
O	965	968	the
O	969	973	sham
O	974	983	treatment
O	984	989	group
O	990	991	(
O	991	992	n
O	992	993	=
B-control-participants	993	995	15
O	995	996	)
O	996	997	,
B-cv-bin-abs	998	1001	one
O	1002	1003	(
B-cv-bin-percent	1003	1004	6
I-cv-bin-percent	1004	1005	.
I-cv-bin-percent	1005	1006	6
I-cv-bin-percent	1006	1007	%
O	1007	1008	)
O	1009	1016	patient
O	1017	1020	had
O	1021	1022	a
B-outcome	1023	1028	grade
I-outcome	1029	1030	0
I-outcome	1031	1039	reaction
O	1039	1040	,
B-cv-bin-abs	1041	1045	four
O	1046	1047	(
B-cv-bin-percent	1047	1049	26
I-cv-bin-percent	1049	1050	.
I-cv-bin-percent	1050	1051	7
I-cv-bin-percent	1051	1052	%
O	1052	1053	)
O	1054	1057	had
B-outcome	1058	1063	grade
I-outcome	1064	1065	1
I-outcome	1066	1075	reactions
O	1075	1076	,
B-cv-bin-abs	1077	1078	9
O	1079	1080	(
B-cv-bin-percent	1080	1082	60
I-cv-bin-percent	1082	1083	.
I-cv-bin-percent	1083	1084	0
I-cv-bin-percent	1084	1085	%
O	1085	1086	)
O	1087	1090	had
B-outcome	1091	1096	grade
I-outcome	1097	1098	2
I-outcome	1099	1108	reactions
O	1108	1109	,
O	1110	1113	and
B-cv-bin-abs	1114	1117	one
O	1118	1119	(
B-cv-bin-percent	1119	1120	6
I-cv-bin-percent	1120	1121	.
I-cv-bin-percent	1121	1122	7
I-cv-bin-percent	1122	1123	%
O	1123	1124	)
O	1125	1128	had
O	1129	1130	a
B-outcome	1131	1136	grade
I-outcome	1137	1138	3
I-outcome	1139	1147	reaction
O	1147	1148	.

B-iv-bin-abs	1149	1152	Two
O	1153	1154	(
B-iv-bin-percent	1154	1156	11
I-iv-bin-percent	1156	1157	.
I-iv-bin-percent	1157	1158	1
I-iv-bin-percent	1158	1159	%
O	1159	1160	)
O	1161	1169	patients
O	1170	1172	in
O	1173	1176	the
O	1177	1180	LED
O	1181	1190	treatment
O	1191	1196	group
O	1197	1200	and
B-cv-bin-abs	1201	1204	one
O	1205	1206	(
B-cv-bin-percent	1206	1207	6
I-cv-bin-percent	1207	1208	.
I-cv-bin-percent	1208	1209	7
I-cv-bin-percent	1209	1210	%
O	1210	1211	)
O	1212	1214	in
O	1215	1218	the
O	1219	1226	control
O	1227	1232	group
O	1233	1236	had
O	1237	1239	to
B-outcome	1240	1249	interrupt
I-outcome	1250	1259	treatment
O	1259	1260	.

O	1261	1272	Differences
O	1273	1280	between
O	1281	1287	groups
O	1288	1292	were
O	1293	1296	not
O	1297	1310	statistically
O	1311	1322	significant
O	1322	1323	.

O	1324	1327	LED
O	1328	1343	photomodulation
O	1344	1347	did
O	1348	1351	not
O	1352	1358	reduce
O	1359	1362	the
O	1363	1372	incidence
O	1373	1375	of
O	1376	1385	radiation
O	1385	1386	-
O	1386	1393	induced
O	1394	1398	skin
O	1399	1408	reactions
O	1409	1411	or
O	1412	1425	interruptions
O	1426	1428	in
O	1429	1436	therapy
O	1436	1437	.

O	1438	1439	.
